Roka Bioscience Company Profile (NASDAQ:ROKA)

About Roka Bioscience (NASDAQ:ROKA)

Roka Bioscience logoRoka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company's Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ROKA
  • CUSIP: N/A
  • Web:
  • Market Cap: $9.61 million
  • Outstanding Shares: 5,007,000
Average Prices:
  • 50 Day Moving Avg: $1.07
  • 200 Day Moving Avg: $2.42
  • 52 Week Range: $0.66 - $7.22
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.97 million
  • Price / Sales: 1.05
  • Book Value: $2.43 per share
  • Price / Book: 0.69
  • EBITDA: ($22,020,000.00)
  • Net Margins: -507.03%
  • Return on Equity: -99.15%
  • Return on Assets: -54.56%
  • Current Ratio: 1.28%
  • Quick Ratio: 1.00%
  • Average Volume: 777,312 shs.
  • Beta: 1.99
  • Short Ratio: 6.13

Frequently Asked Questions for Roka Bioscience (NASDAQ:ROKA)

What is Roka Bioscience's stock symbol?

Roka Bioscience trades on the NASDAQ under the ticker symbol "ROKA."

How were Roka Bioscience's earnings last quarter?

Roka Bioscience, Inc. (NASDAQ:ROKA) released its quarterly earnings data on Thursday, May, 11th. The company reported ($1.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.19) by $0.34. The company earned $2.04 million during the quarter. Roka Bioscience had a negative return on equity of 99.15% and a negative net margin of 507.03%. View Roka Bioscience's Earnings History.

Where is Roka Bioscience's stock going? Where will Roka Bioscience's stock price be in 2017?

1 brokers have issued 12 month price objectives for Roka Bioscience's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Roka Bioscience's stock price to reach $10.00 in the next year. View Analyst Ratings for Roka Bioscience.

Who are some of Roka Bioscience's key competitors?

Who are Roka Bioscience's key executives?

Roka Bioscience's management team includes the folowing people:

  • Paul G. Thomas, Chairman of the Board
  • Mary Duseau, President, Chief Executive Officer, Secretary, Director
  • Lars Boesgaard, Chief Financial Officer
  • Nicholas J. Valeriani, Director
  • Fred E. Cohen Ph.D. M.D., Independent Director
  • Michael P. Doyle Ph.D., Independent Director
  • David W. J. McGirr, Independent Director
  • Jonathan Todd Silverstein J.D., Independent Director

Who owns Roka Bioscience stock?

Roka Bioscience's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ORBIMED ADVISORS LLC (24.91%), ORBIMED ADVISORS LLC (22.36%), ORBIMED ADVISORS LLC (13.86%), ORBIMED ADVISORS LLC (10.24%), SHANSAB TAMIM (5.40%) and SHANSAB TAMIM (4.67%). View Institutional Ownership Trends for Roka Bioscience.

How do I buy Roka Bioscience stock?

Shares of Roka Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Roka Bioscience's stock price today?

One share of Roka Bioscience stock can currently be purchased for approximately $1.67.

MarketBeat Community Rating for Roka Bioscience (NASDAQ ROKA)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Roka Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Roka Bioscience (NASDAQ:ROKA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (498.80% upside)
Consensus Price Target History for Roka Bioscience (NASDAQ:ROKA)
Price Target History for Roka Bioscience (NASDAQ:ROKA)
Analysts' Ratings History for Roka Bioscience (NASDAQ:ROKA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/12/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
3/6/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
11/12/2015WedbushLower Price TargetNeutral$3.00 -> $2.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Roka Bioscience (NASDAQ:ROKA)
Earnings by Quarter for Roka Bioscience (NASDAQ:ROKA)
Earnings History by Quarter for Roka Bioscience (NASDAQ ROKA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($1.19)($1.53)$2.04 millionViewN/AView Earnings Details
11/7/2016Q316($5.39)$1.50 million$1.90 millionViewListenView Earnings Details
5/4/2016Q116($0.46)($0.47)$1.56 million$1.60 millionViewN/AView Earnings Details
3/4/2016Q415($0.48)($0.56)$1.63 million$1.50 millionViewN/AView Earnings Details
11/11/2015Q315($0.53)($0.49)$1.75 million$1.50 millionViewN/AView Earnings Details
8/13/2015Q215($0.51)($0.54)$1.58 million$1.50 millionViewN/AView Earnings Details
5/7/2015Q115($0.50)($0.51)$1.44 million$1.51 millionViewN/AView Earnings Details
3/26/2015Q414($0.52)($0.43)$1.44 million$1.36 millionViewN/AView Earnings Details
11/6/2014($0.49)($0.64)$2.11 million$1.48 millionViewN/AView Earnings Details
8/11/2014Q214($11.28)$1.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Roka Bioscience (NASDAQ:ROKA)
2017 EPS Consensus Estimate: ($4.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.19)($1.19)($1.19)
Q2 20171($1.14)($1.14)($1.14)
Q3 20171($1.08)($1.08)($1.08)
Q4 20171($1.03)($1.03)($1.03)
(Data provided by Zacks Investment Research)


Dividend History for Roka Bioscience (NASDAQ:ROKA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Roka Bioscience (NASDAQ:ROKA)
Insider Ownership Percentage: 29.20%
Institutional Ownership Percentage: 66.51%
Insider Trades by Quarter for Roka Bioscience (NASDAQ:ROKA)
Institutional Ownership by Quarter for Roka Bioscience (NASDAQ:ROKA)
Insider Trades by Quarter for Roka Bioscience (NASDAQ:ROKA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Orbimed Advisors LlcMajor ShareholderSell201,617$0.68$137,099.56View SEC Filing  
9/29/2017Orbimed Advisors LlcMajor ShareholderSell474,676$0.72$341,766.72View SEC Filing  
9/27/2017Orbimed Advisors LlcMajor ShareholderSell127,601$0.98$125,048.98View SEC Filing  
8/24/2017Orbimed Advisors LlcMajor ShareholderSell14,300$1.50$21,450.00View SEC Filing  
8/23/2017Orbimed Advisors LlcMajor ShareholderSell1,100$1.50$1,650.00View SEC Filing  
8/22/2017Orbimed Advisors LlcMajor ShareholderSell75,276$1.52$114,419.52View SEC Filing  
11/17/2014David W J McgirrDirectorBuy50,000$3.60$180,000.00View SEC Filing  
7/22/2014Patrick J KerinsMajor ShareholderBuy383,333$12.00$4,599,996.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Roka Bioscience (NASDAQ:ROKA)
Latest Headlines for Roka Bioscience (NASDAQ:ROKA)
DateHeadline logoBRIEF-Edward Painter reports 6.79 pct stake in Roka Bioscience - October 11 at 7:15 AM logoHead to Head Review: Agenus (AGEN) versus Roka Bioscience (ROKA) - October 7 at 8:24 PM logoBRIEF-Orbimed Advisors cuts stake in Roka Bioscience to 10.24 pct - SEC filing - October 6 at 7:28 AM logoRoka Bioscience, Inc. (ROKA) Major Shareholder Sells $137,099.56 in Stock - October 5 at 7:46 PM logoRoka Bioscience, Inc. (ROKA) Major Shareholder Orbimed Advisors Llc Sells 474,676 Shares - October 2 at 7:43 PM logoROKA BIOSCIENCE, INC. - - September 28 at 8:03 PM logoOrbimed Advisors Llc Sells 127,601 Shares of Roka Bioscience, Inc. (ROKA) Stock - September 28 at 7:48 PM logoRoka Bioscience, Inc. :ROKA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 - August 26 at 8:55 AM logoRoka Bioscience, Inc. (ROKA) Major Shareholder Sells $21,450.00 in Stock - August 25 at 4:32 PM logoRoka Bioscience, Inc. (ROKA) Major Shareholder Sells $114,419.52 in Stock - August 22 at 10:20 PM logoRoka Bioscience (ROKA) to Sell its Assets to Subsidiary of Institute for Environmental Health for $17.5M - August 17 at 9:13 PM logoBRIEF-Roka Bioscience agrees to sell its assets to subsidiary of Institute for Environmental Health - August 17 at 9:13 PM logoRoka Bioscience, Inc. Agrees to Sell its Assets to Subsidiary of Institute for Environmental Health, Inc. - August 17 at 4:12 PM logoBRIEF-Tamim Shansab reports 5.4 pct passive stake in Roka Bioscience - July 29 at 6:52 AM logoRoka Bioscience to Co-Present Industry Webinar - Game of Zones: A Practical Guide to Listeria Monitoring and Detection - July 27 at 6:57 AM logoRoka Bioscience Announces AOAC Certification for 18-hour Sample Enrichment using ActeroTM ELITE Listeria Enrichment Media and the Atlas® Listeria Environmental Assay - July 11 at 4:33 PM logoRoka Bioscience to Present at the International Association of Food Protection Conference - July 8 at 2:07 PM logoRoka Bioscience (ROKA) Enters Distribution Partnership with FoodChek Systems - May 9 at 10:45 AM logoBRIEF-Roka Bioscience says entered into 5-year non-exclusive distribution agreement with Foodchek Systems Inc - May 9 at 10:45 AM logoFood Safety Testing Market Size to Reach USD 8.04 Billion by 2021: Zion Market Research - April 28 at 3:44 PM logoRoka Bioscience to participate in the 40th Annual National Food Policy Conference - PR Newswire (press release) - April 11 at 9:57 AM logoRoka Bioscience, Inc. :ROKA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017 - March 24 at 7:25 PM logoROKA BIOSCIENCE, INC. Files SEC form 10-K, Annual Report - March 20 at 5:40 PM logoRoka Bioscience Reports Fourth Quarter and Full Year 2016 Financial Results - March 9 at 7:34 PM logoQ4 2016 Roka Bioscience Inc Earnings Release - After Market Close - March 9 at 8:09 AM logoROKA BIOSCIENCE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements a - March 1 at 10:13 AM logo4:16 pm Roka Bioscience appoints Mary Duseau as President and CEO effective today - January 18 at 12:58 AM logoROKA BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit - January 17 at 7:56 PM logoROKA BIOSCIENCE, INC. Files SEC form 10-Q, Quarterly Report - November 8 at 7:01 PM logoROKA BIOSCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition - November 7 at 8:01 PM logoQ3 2016 Roka Bioscience Inc Earnings Release - After Market Close - November 7 at 11:09 AM logoROKA BIOSCIENCE, INC. Files SEC form 8-K, Other Events - November 1 at 7:25 PM logoRoka Bioscience to Report Third Quarter 2016... - October 31 at 6:56 PM logoLeading Subject Matter Experts Will Address Key Issues and Solutions at Food Safety Summit Resource Center at PACK EXPO - October 27 at 7:13 PM logoRoka Bioscience (ROKA) to Effect 1-for-10 Reverse Stock Split - October 12 at 7:02 PM logoROKA BIOSCIENCE, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year - October 11 at 7:26 PM logoROKA BIOSCIENCE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec - September 22 at 11:55 AM logoRoka Bioscience (ROKA) Prices $22.5M Series A Preferred Stock Private Placement - September 18 at 11:17 AM logoROKA BIOSCIENCE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi - September 16 at 6:51 PM



Roka Bioscience (ROKA) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.